Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments

Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches.